In an epidemiological study of the incidence of ulcerative colitis (UC) in the county of Stockholm between 1955Stockholm between and 1979Stockholm between , 1274 (p<O-OOOl). The number of patients with UC who developed PSC remained constant during the study period. Thus, although evidence of abnormal liver function is a common finding in UC, a spontaneous return to normal levels is common. In this study, which did not have a selection bias, the median time of survival among PSC patients was far longer than previously described although development of PSC among patients with UC does significantly reduce the estimated median time of survival.
Abstract
In an epidemiological study of the incidence of ulcerative colitis (UC) 21 patients, nine ofwhich had a chronic, but non-fatal course. Twenty nine (2.3%) of the patients developed primary sclerosing cholangitis (PSC), and 12 of them died during the study period four because of cholangiocarcinoma and eight because of hepatic failure; one patient had a transplant. The estimated median time of survival from the first presentation of evidence of a liver function, compatible with the diagnosis of PSC, to death or liver transplantation was 21 years. A comparison of survival rates in patients with UC and patients with UC and concurrent PSC showed, a significant reduction in survival in the PSC group (p<O-OOOl). The number of patients with UC who developed PSC remained constant during the study period. Thus, although evidence of abnormal liver function is a common finding in UC, a spontaneous return to normal levels is common. In this study, which did not have a selection bias, the median time of survival among PSC patients was far longer than previously described although development of PSC among patients with UC does significantly reduce the estimated median time of survival. (Gut 1994; 35: [84] [85] [86] [87] [88] [89] The association of ulcerative colitis (UC) and liver disease was first described in 1873 and was followed by numerous surveys of liver dysfunction in UC. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] after the onset of the bowel disease. Two patients had significantly increased alkaline phosphatase activities and morphological changes in liver biopsy specimens compatible with a diagnosis of PSC. Both patients had, however, repeated normal ERCPs and were therefore believed to be suffering from sclerosing cholangitis of the small bile ducts.19 In one of these patients, histological progression of the cholangitis to bridging fibrosis and cirrhosis was noted. Taking these two patients into account 2-3%, of the UC patients had PSC.
Twelve ofthe PSC patients were dead at follow up, eight because of hepatic failure and four because of cholangiocarcinoma. One had a liver transplant. The median time of survival for the entire PSC group was 21 years (range 6-44) (Fig  2) . Nine of the PSC patients had a colectomy. This procedure did not seem to improve the liver disease, as judged from biochemical tests.
Among the whole group of patients with UC and abnormal liver function tests, 34 died and one had a transplant during the study period . A necropsy was carried out on all but one of the patients who died (Table IV) . Amnong these, only three were known to have had transient abnormalities of liver function tests; the remaining 31 patients had abnormal liver function tests at death. Eighteen patients died because of liver failure or primary malignancy of the liver or bile ducts, and one patient had liver transplantation because of liver failure. Survival analysis of all UC patients with hepatobiliary dysfunction, compared with patients with UC only, did not show any significant differences (data not shown). Survival analysis of all UC patients without PSC, however, compared with patients with both UC and PSC, showed a significant reduced survival for the PSC group (p<0-0001) (Fig 3) . Fatty change of the liver is a well known abnormality in UC and also a common finding in patients having colectomy' 23; furthermore, this change has been suggested to be related to the severity of the colitis.4 In this study, fatty change was found in all patients with abnormal liver function tests and active colitis in which a liver biopsy specimen was obtained. Therefore, it may be suspected that the fatty change in this subgroup of UC patients is an unspecific manifestation of the accompanying malnutrition, anaemia, and treatment with corticosteroids. Eleven patients, however, had fatty change unrelated to the activity of the colitis, a finding that might be explained by overweight or overconsumption of alcohol. Fatty change is an unspecific and common cause for a rise in serum transaminase activities in asymptomatic patients and also in asymptomatic patients without UC. 16 Chronic autoimmune hepatitis has been reported to be associated with ulcerative colitis. 6 Because, in the quoted study, however, no clear distinction between PSC was made, some patients may well have been suffering from this disease. In our study, only three cases with autoimmune hepatitis were found. One patient was found to have primary biliary cirrhosis, previously described in association with UC in only five cases in published works. In our study four PSC patients died of cholangiocarcinoma, which is known to be associated with both UC and PSC.28 All patients with cholangiocarcinoma also had PSC; therefore it seems probable that this particular subset of patients with UC also has an increased risk of developing cholangiocarcinoma. Occurrence of cholangiocarcinoma in 14% (4/29) of our PSC patients is a high figure when compared with the results in other studies.5' 101129 The explanation for the differences in the results may be that all PSC patients who died had a postmortem examination and the diagnoses could be verified whereas there are apparent problems in diagnosing cholangiocarcinoma in living patients with PSC.
Patients with PSC may have a highly variable course, many remaining well and asymptomatic during the entire study period. The estimated median time of survival for all PSC patients was 21 years (range . Recently, one study from the Mayo Clinic and one from King's College on PSC have shown an overall survival of 1L7 and 12 years, respectively.'0 1' It is important to note that in these two studies both start and endpoints of PSC were defined in different ways therefore no real comparison can be made. The English study and our study, however, both define onset of PSC as the time of the first presentation of abnormal liver function tests or symptoms consistent with the diagnosis of PSC, and endpoint as either liver related death or liver transplantation. The much higher median survival found in our study is therefore probably explained by the fact that it lacks the selection bias found in the English one.
Thus, it can be concluded that although 11% of all patients with UC presented with evidence of abnormal liver function tests, a return to normal occurred spontaneously in many cases. The need for blood transfusions among these patients, and the subsequent transmission of viral infections can explain the frequent finding of hepatitis among UC patients. With the increased and improved testing of blood products, infections of this kind will hopefully be something ofthe past in coming years. PSC is the most common chronic liver disease associated with UC. Although the median time of survival for the PSC patients in our study is much longer than described previously, patients with UC and a concurrent PSC are likely to have a significantly reduced survival time compared with patients with UC only.
